Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Cancer Immunology, Immunotherapy : CII
Alexander J MullerGeorge C Prendergast

Abstract

Indoleamine 2,3-dioxygenase (IDO) is generally considered to be immunosuppressive but recent findings suggest this characterization oversimplifies its role in disease pathogenesis. Recently, we showed that IDO is essential for tumor outgrowth in the classical two-stage model of inflammatory skin carcinogenesis. Here, we report that IDO loss did not exacerbate classical inflammatory responses. Rather, IDO induction could be elicited by environmental signals and tumor promoters as an integral component of the inflammatory tissue microenvironment even in the absence of cancer. IDO loss had limited impact on tumor outgrowth in carcinogenesis models that lacked an explicit inflammatory tumor promoter. In the context of inflammatory carcinogenesis where IDO was critical to tumor development, the most important source of IDO was radiation-resistant non-hematopoietic cells, consistent with evidence that loss of the IDO regulatory tumor suppressor gene Bin1 in transformed skin cells facilitates IDO-mediated immune escape by a cell autonomous mechanism. Taken together, our results identify IDO as an integral component of 'cancer-associated' inflammation that tilts the immune system toward tumor support. More generally, they promote the c...Continue Reading

References

May 1, 1991·The Journal of Experimental Medicine·R R HardyK Hayakawa
Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·S SayamaO Hayaishi
Mar 7, 2001·Lancet·F Balkwill, A Mantovani
Dec 20, 2002·Nature·Lisa M Coussens, Zena Werb
Mar 4, 2003·Nature Immunology·Jason D FontenotAlexander Y Rudensky
Aug 7, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrew L MellorDavid H Munn
Sep 19, 2003·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Cory M RobinsonJoseph M Carlin
Jul 16, 2004·The Journal of Clinical Investigation·David H MunnAndrew L Mellor
Aug 17, 2004·Immunity·Gavin P DunnRobert D Schreiber
Mar 16, 2005·Cancer Cell·Frances BalkwillAlberto Mantovani
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aikou OkamotoMitsuyoshi Urashima
Feb 7, 2006·Current Opinion in Immunology·Ping YuHans Schreiber
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gerald BrandacherAlbert Amberger
Jul 25, 2006·Nature Reviews. Cancer·Alexander J Muller, Peggy A Scherle
Aug 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gargi D BasuPinku Mukherjee
Sep 16, 2006·Immunological Reviews·David H Munn, Andrew L Mellor
Nov 23, 2006·British Journal of Cancer·K InoF Kikkawa
Dec 28, 2006·Dermatology : International Journal for Clinical and Investigative Dermatology·Georg WeinlichDietmar Fuchs
Jan 11, 2007·Cancer Research·Mee Young ChangGeorge C Prendergast
Jan 11, 2007·The Journal of Experimental Medicine·Bin ZhangHans Schreiber
Feb 20, 2007·Current Cancer Drug Targets·Alexander J Muller, George C Prendergast
Mar 27, 2007·Nature Reviews. Cancer·Erin M Griner, Marcelo G Kazanietz
Apr 7, 2007·Cancer Research·George C Prendergast, Elizabeth M Jaffee
May 4, 2007·The Journal of Clinical Investigation·David H Munn, Andrew L Mellor
Aug 19, 2007·Cancer Research·Mee Young ChangGeorge C Prendergast
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas F Gajewski
Nov 21, 2007·Nature·Catherine M KoebelRobert D Schreiber
Apr 29, 2008·Journal of Cancer Research and Clinical Oncology·Ke PanJian-chuan Xia
Oct 28, 2008·Proceedings of the National Academy of Sciences of the United States of America·Alexander J MullerAndrew L Mellor
May 30, 2009·Journal of the American College of Surgeons·Agnieszka K WitkiewiczJonathan R Brody
Oct 6, 2009·Clinical & Experimental Metastasis·Hiroshi UrakawaNaoki Ishiguro
Feb 18, 2010·Cancer Research·Alexander J MullerGeorge C Prendergast

❮ Previous
Next ❯

Citations

Jul 24, 2012·Cancer Discovery·Courtney SmithAlexander J Muller
Jan 30, 2014·Marine Drugs·Valentin A Stonik, Sergey N Fedorov
Jan 10, 2014·International Immunology·Richard MetzGeorge C Prendergast
Apr 9, 2014·Cancer Immunology, Immunotherapy : CII·George C PrendergastAlexander J Muller
Dec 26, 2013·Cancer Immunology, Immunotherapy : CII·Jürgen C BeckerMads Hald Andersen
Jun 28, 2011·Human Immunology·Dagmar von BubnoffThomas Bieber
Sep 15, 2012·Radiation Research·Carl N SprungPeter A W Rogers
Apr 4, 2017·International Immunopharmacology·Fangxuan LiJuntian Liu
Jul 18, 2015·Clinical Science·Amanda W S YeungShane R Thomas
Feb 3, 2019·Cells·Charlotte DomblidesBenjamin Faustin
Jan 1, 2014·Oncoimmunology·Stine Kiaer LarsenMads Hald Andersen
Sep 26, 2020·Frontiers in Immunology·Lauren M F MerloLaura Mandik-Nayak
Jul 1, 2018·Cancer Immunology, Immunotherapy : CII·Zachary J BrownTim F Greten
Sep 27, 2018·Frontiers in Oncology·Eric FoxGeorge C Prendergast
Jul 29, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lijie ZhaiDerek A Wainwright
Dec 17, 2017·Cancer Research·George C PrendergastAlexander J Muller
Nov 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lijie ZhaiDerek A Wainwright
Jun 5, 2021·Cellular and Molecular Gastroenterology and Hepatology·Xin ZhangRong Hu
Jun 26, 2018·Chemical Reviews·Jessica L CounihanDaniel K Nomura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.